Portada›Viernes 26 de septiembre de 2025

Biomédicas del NASDAQ ante la SEC, viernes 26 de septiembre de 2025

Los 35 documentos que 29 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.

← jueves 25 de septiembre de 2025 · lunes 29 de septiembre de 2025 →

¿Lo quieres en tu correo cada mañana, y solo de tus empresas? Crear una cuenta.

Emisiones y dilución

1. ASBPAspire-Lakewood Holdings, Inc.S-1/ACapacidad de emisión registrada (enmienda)EDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …going concern considerations in accordance with Financial Accounting Standard Board’s (“FASB”) ASC Subtopic 205-40, “Going Concern,” management has determined that the Company’s liquidity condition raises substantial doubt about the Company’s ability to continue as a going concern through twelve months from the date these condensed consolidated financial statements are available to be issued. These condensed consolidated financial statements do not include any adjustments relating…
2. HURATuHURA Biosciences, Inc./NV424B3Prospecto suplementario o de reventaEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …ownership interest. A decline in the value of TuHURA could also cause you to lose all or part of your investment. 6 Table of Contents TuHURA’s recurring losses from operations and financial condition raise substantial doubt about its ability to continue as a going concern. TuHURA’s recurring losses from operations and financial condition raise substantial doubt about its ability to continue as a going concern. In TuHURA’s financial statements for the six months ended June…

   En el documentoContrasplit de accionestexto original ▸

   …Merger Sub merged with and into TuHURA, with TuHURA surviving the Merger and becoming direct, wholly owned subsidiary of the Company. Effective at 12:01 a.m. Eastern Time on October 18, 2024, the Company effected the Reverse Stock Split, whereby every 35 shares of issued and outstanding common stock were converted into one share of common stock. Any fractional shares of common stock resulting from the Reverse Stock Split were rounded…
3. SLXNSilexion Therapeutics CorpS-3Capacidad de emisión registradaEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …included in its opinion for the years ended December 31, 2024 and 2023 an explanatory paragraph referring to our recurring losses from operations and our cash outflows from operating activities that raise substantial doubt about our ability to continue as a going concern. If we encounter continued issues or delays in the development or commercialization of our product candidates, or if we incur greater than anticipated expenses, our prior losses and expected future losses…

   En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

   …any jurisdiction where the offer or sale is not permitted. PROSPECTUS SUPPLEMENT SUBJECT TO COMPLETION, DATED SEPTEMBER 26, 2025 Silexion Therapeutics Corp Up to $13,170,000 of Ordinary Shares We have entered into an At The Market Offering Agreement (the “Sales Agreement”), dated September 26, 2025, with H.C. Wainwright & Co., LLC, as sales agent or principal (“Wainwright” or the “sales agent”), relating to the sale of our ordinary shares…
4. SNGXSOLIGENIX, INC.424B4Nueva emisión de acciones con precioEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …have incurred significant losses since inception and expect to continue to incur losses for the foreseeable future, which together with our negative cash flows and auditor’s going concern opinion raise substantial doubt about our ability to continue as a going concern without obtaining additional capital. ​ • We expect a number of factors to cause our operating results to fluctuate on a quarterly and annual basis, which may make it difficult to predict our future performance…

   En el documentoContrasplit de accionestexto original ▸

   …However, there can be no assurances that it can consummate such a transaction, or consummate a transaction at favorable pricing. ​ F-27 TABLE OF CONTENTS Reverse Stock Split On June 5, 2024, the Company completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of one-for-sixteen, whereby every sixteen shares of the Company’s issued and outstanding common stock were automatically combined into one…
5. TVGNTevogen Inc.424B3Prospecto suplementario o de reventaEDGAR

Participaciones y control

1. EPRXEUPRAXIA PHARMACEUTICALS INC.SC 13D/ACambio en participación significativaEDGAR
2. SCLXScilex Holding CoSC 13DCambio en participación significativaEDGAR

Informes y hechos relevantes

1. ANIPANI PHARMACEUTICALS INC8-KVenta de acciones no registrada (colocación privada)EDGAR
2. ASBPAspire-Lakewood Holdings, Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …an adverse opinion or a disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting principles, other than that it included an explanatory paragraph regarding substantial doubt as to the Company’s ability to continue as a going concern. During the year ended December 31, 2024 and the subsequent interim periodsthrough September 22, 2025, there were no “disagreements” (as such term is defined in Item 304(a)(1)(iv) of Regulation S-K and…
3. HROWHARROW, INC.8-KVenta de acciones no registrada (colocación privada)EDGAR
4. LGVNLongeveron Inc.8-KAviso de incumplimiento de cotizaciónEDGAR
5. ONCOOnconetix, Inc.8-KFin de acuerdo materialEDGAR
6. SCLXScilex Holding Co8-KVenta de acciones no registrada (colocación privada)EDGAR
7. TVGNTevogen Inc.8-KAviso de incumplimiento de cotizaciónEDGAR
8. VERUVERU INC.8-KFin de acuerdo materialEDGAR
9. BMRABIOMERICA INC10-K/AInforme anual (enmienda)EDGAR
10. CRNXCrinetics Pharmaceuticals, Inc.8-KOtros hechos relevantesEDGAR
11. DERMJourney Medical Corp8-KNuevo acuerdo materialEDGAR
12. ESLAEstrella Immunopharma, Inc.8-KCambio en el consejo o la direcciónEDGAR
13. LFCRLIFECORE BIOMEDICAL, INC. \DE\8-KCambio en el consejo o la direcciónEDGAR
14. LITSLite Strategy, Inc.10-KInforme anualEDGAR
15. LPCNLipocine Inc.8-KOtros hechos relevantesEDGAR
16. MBXMBX Biosciences, Inc.8-KNuevo acuerdo materialEDGAR
17. NRXPNRX Pharmaceuticals, Inc.8-KOtros hechos relevantesEDGAR
    En el documentoDesignación de terapia innovadora (breakthrough)texto original ▸

    …ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has recently had a Suitability Petition granted, allowing re-filing of an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application…

    En el documentoDesignación de vía rápida (Fast Track)texto original ▸

    …disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has…
18. PALIPALISADE BIO, INC.8-KOtros hechos relevantesEDGAR
19. PEPGPepGen Inc.8-KNuevo acuerdo materialEDGAR
20. QCLSQ/C TECHNOLOGIES, INC.8-KCambio de estatutosEDGAR
21. QNCXQuince Therapeutics, Inc.8-KNuevo acuerdo materialEDGAR
22. SABSSAB Biotherapeutics, Inc.8-KCambio en el consejo o la direcciónEDGAR
23. SCLXScilex Holding Co8-KCambio en el consejo o la direcciónEDGAR
    En el documentoCambio en la dirección de la empresatexto original ▸

    …Board”) has decreased the size of the Board from six directors to five directors as of immediately following the Effective Time. Additionally, as of immediately following the Effective Time, the Board has appointed Stephen Ma, the Chief Financial Officer, Senior Vice President and Secretary of the Company, to fill the vacancy on the Board resulting from the resignations and decrease in the size of the Board. There are no family relationships between Mr…
24. SCLXScilex Holding Co8-KNuevo acuerdo materialEDGAR
25. SLXNSilexion Therapeutics Corp8-KNuevo acuerdo materialEDGAR
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

    …accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 1.01 Entry into a Material Definitive Agreement. On September 26, 2025, Silexion Therapeutics Corp (the “Company”), entered into an At The Market Offering Agreement, (the “Offering Agreement”), with H.C. Wainwright & Co., LLC, as agent (“Wainwright”), pursuant to which the Company may offer and sell, from time to time through Wainwright ordinary shares…

Juntas de accionistas

1. BFRGBullFrog AI Holdings, Inc.DEF 14AConvocatoria de junta de accionistasEDGAR
   En el documentoContrasplit de accionestexto original ▸

   …the Board has unanimously recommended that the proposed amendment be presented to our stockholders for approval. Board Discretion to Implement the Reverse Stock Split The Reverse Stock Split will be effected, if at all, only upon a determination by our Board that the Reverse Stock Split (with an Exchange Ratio determined by our Board as described above) remains in the best interests of the Company, after receipt of stockholder approval, for purposes of maintaining the listing of our…
2. CTORCITIUS ONCOLOGY, INC.DEF 14AConvocatoria de junta de accionistasEDGAR
3. TLRYTilray Brands, Inc.DEF 14AConvocatoria de junta de accionistasEDGAR

← jueves 25 de septiembre de 2025 · lunes 29 de septiembre de 2025 →

Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.